Tag #Huntington's Disease

Showing 1 to 7 of 7 results

dw.com

🌐 90% Global Worthiness

Sep 26, 01:14

Huntington's Disease Progression Slowed by 75% in Clinical Trial

British researchers announced a 75% reduction in Huntington's disease progression over 36 months in a clinical trial of 29 patients using a new gene therapy, AMT-130, developed with UniQure.

Huntington's Disease Progression Slowed by 75% in Clinical Trial

British researchers announced a 75% reduction in Huntington's disease progression over 36 months in a clinical trial of 29 patients using a new gene therapy, AMT-130, developed with UniQure.

Progress

16% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the next steps and potential long-term implications of this breakthrough?

UniQure plans to seek accelerated FDA approval in early 2026, followed by UK and European applications. Successful approval would represent a major advance in treating this currently incurable disease, potentially improving patients' quality of life significantly.

edition.cnn.com

🌐 90% Global Worthiness

Sep 25, 10:19

UniQure's Gene Therapy Shows Promise in Slowing Huntington's Disease Progression

A Phase 1/2 study by uniQure showed a 75% reduction in Huntington's disease progression in patients receiving a high dose of AMT-130 gene therapy after 36 months, marking a potential breakthrough in treating this currently incurable condition.

UniQure's Gene Therapy Shows Promise in Slowing Huntington's Disease Progression

A Phase 1/2 study by uniQure showed a 75% reduction in Huntington's disease progression in patients receiving a high dose of AMT-130 gene therapy after 36 months, marking a potential breakthrough in treating this currently incurable condition.

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the primary impact of uniQure's Phase 1/2 study results on Huntington's disease treatment?

The study's findings demonstrate a 75% reduction in Huntington's disease progression in patients given a high dose of AMT-130, representing a significant step towards the first disease-modifying treatment. This could fundamentally change the treatment landscape, moving beyond symptom management to directly slowing disease progression.

bbc.com

🌐 95% Global Worthiness

Sep 24, 16:19

Huntington's Disease Treatment Shows 75% Slowdown in Clinical Progression

A new gene therapy has demonstrated a 75% slowdown of Huntington's disease progression in a clinical trial, offering a potential life-extending treatment for those affected.

Huntington's Disease Treatment Shows 75% Slowdown in Clinical Progression

A new gene therapy has demonstrated a 75% slowdown of Huntington's disease progression in a clinical trial, offering a potential life-extending treatment for those affected.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does this gene therapy work, and what are its limitations?

The therapy uses a modified virus to deliver a DNA sequence into the brain, silencing the gene responsible for producing the toxic huntingtin protein. The 12-18 hour neurosurgery involved limits accessibility due to complexity and anticipated high cost; the therapy's efficacy was shown in 29 patients and not yet peer-reviewed.

abcnews.go.com

🌐 85% Global Worthiness

Jan 16, 19:09

Huntington's Disease: CAG Repeat Expansion Identified as Key Disease Mechanism

New research shows that the Huntington's disease mutation, involving a repeated DNA sequence (CAG), expands over time, remaining harmless until it surpasses 150 repeats, triggering toxic protein production and neuronal death; this discovery could lead to new treatment strategies.

Huntington's Disease: CAG Repeat Expansion Identified as Key Disease Mechanism

New research shows that the Huntington's disease mutation, involving a repeated DNA sequence (CAG), expands over time, remaining harmless until it surpasses 150 repeats, triggering toxic protein production and neuronal death; this discovery could lead to new treatment strategies.

Progress

0% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the key mechanism by which the Huntington's disease mutation causes neuronal damage, and what is its clinical significance?

Huntington's disease, a fatal hereditary disorder, is caused by a genetic mutation where a DNA sequence (CAG) repeats at least 40 times. This mutation remains harmless for decades but expands over time, eventually exceeding a threshold of about 150 repeats, leading to toxic protein production and neuronal death.

cnnespanol.cnn.com

🌐 90% Global Worthiness

Sep 25, 07:18

Experimental Gene Therapy Shows Significant Slowdown in Huntington's Disease Progression

A Phase 1/2 study by uniQure showed that a high dose of their gene therapy, AMT-130, slowed Huntington's disease progression by 75% in patients after 36 months, marking a potential breakthrough for the currently incurable disease.

Experimental Gene Therapy Shows Significant Slowdown in Huntington's Disease Progression

A Phase 1/2 study by uniQure showed that a high dose of their gene therapy, AMT-130, slowed Huntington's disease progression by 75% in patients after 36 months, marking a potential breakthrough for the currently incurable disease.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the next steps and potential future implications of this research?

uniQure plans to submit data to the FDA in Q1 2026, with potential market launch by the end of 2027 if approved. While further research is necessary, this success could accelerate the development of similar one-time, precision gene therapies for other neurological diseases. The reduction in neurofilament light protein levels further supports the positive effects of this treatment.

liberation.fr

🌐 90% Global Worthiness

Sep 25, 22:16

Huntington's Disease Treatment Shows Significant Progress

British researchers announced a new gene therapy that slowed Huntington's disease progression by 75% in a clinical trial of 29 patients over 36 months, offering a potential breakthrough for the 6,000 individuals in France affected by this neurodegenerative disorder.

Huntington's Disease Treatment Shows Significant Progress

British researchers announced a new gene therapy that slowed Huntington's disease progression by 75% in a clinical trial of 29 patients over 36 months, offering a potential breakthrough for the 6,000 individuals in France affected by this neurodegenerative disorder.

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the future implications and limitations of this gene therapy?

While promising, further testing is needed to evaluate long-term effects, potential side effects, and overall efficacy. The success in this trial suggests a potential paradigm shift in Huntington's disease treatment, offering hope for improved quality of life for patients, but larger-scale trials and extended follow-up are crucial before widespread application.

theguardian.com

🌐 75% Global Worthiness

Jan 22, 22:10

Journalist Charlotte Raven dies at 55, advocating for assisted dying

Charlotte Raven, a journalist and editor known for her work at the Guardian and New Statesman, died at 55 after a battle with Huntington's disease; her powerful writing on assisted dying highlighted systemic failures in palliative care.

Journalist Charlotte Raven dies at 55, advocating for assisted dying

Charlotte Raven, a journalist and editor known for her work at the Guardian and New Statesman, died at 55 after a battle with Huntington's disease; her powerful writing on assisted dying highlighted systemic failures in palliative care.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What were the most significant impacts of Charlotte Raven's career and advocacy?

Charlotte Raven, a prominent journalist and editor, died at 55. Her career, marked by influential work at publications like the Guardian and New Statesman, was cut short by Huntington's disease. She advocated powerfully for assisted dying in her later years, highlighting the inadequacies of palliative care.

Showing 1 to 7 of 7 results